The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (JCOG1106).
 
Akira Fukutomi
Honoraria - Daiichi Sankyo; Lilly Japan; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Yakult Honsha
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); OncoTherapy Science (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Yakult Honsha (Inst)
 
Junki Mizusawa
Honoraria - Chugai Pharma
 
Hiroshi Katayama
No Relationships to Disclose
 
Satoaki Nakamura
No Relationships to Disclose
 
Yoshinori Ito
No Relationships to Disclose
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Tatsuya Ioka
Honoraria - Merck Serono; Taiho Pharmaceutical
Speakers' Bureau - Chugai Pharma; Eisai; Janssen; Lilly; Mochida Pharmaceutical Co. Ltd.; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kowa (Inst); Merck Serono (Inst); Nihon Zouki (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Makoto Ueno
Honoraria - Abbott Diagnostics; Lilly
Research Funding - Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Zeria Pharmaceutical
 
Masafumi Ikeda
Consulting or Advisory Role - NanoCarrier
Speakers' Bureau - Abbott Diagnostics; Bayer Yakuhin; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Guerbet; Kyowa Hakko Kirin; Merck Serono; Novartis; Takeda; Yakult Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Kazuya Sugimori
No Relationships to Disclose
 
Kyoko Shimizu
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly Japan; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sceti Medical Labo (Inst); Shizuoka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Masato Ozaka
No Relationships to Disclose
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Shoji Nakamori
No Relationships to Disclose
 
Takeshi Azuma
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Taiho Pharmaceutical (Inst)
 
Naohiro Sata
No Relationships to Disclose
 
Tetsuya Mine
No Relationships to Disclose
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Nippon Kayaku; Ono Pharmaceutical; Sandoz; Sanofi; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Eisai; Fujifilm; GlaxoSmithKline; J-Pharma; Janssen; Kowa; Kyowa Hakko Kirin; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)